Bella specialises in the production of creams, lotions, ointments, liquids, gels and pastes

• licensed TGA manufacturer, practicing GMP in an A2 rated professional facility
• cosmetic and pharmaceutical products for third party clients, specialises in both the toll and contract manufacture
• conducts research, development and testing of new formulations for third party clients

Investment Thesis

Producing a high quality products which has been trusted by customers for 25 years

• manufacturing business operating out of Sydney’s outer suburbs
• client list consists of mostly Australian or large multinational companies
• services the pharmaceutical manufacturing needs of 21 clients, some of these have been customers for 10 plus years

Manufacturing plant & equipment and production expertise

• increased production capacity now exceeds 25,000 litres, with further expansion opportunity
• product development, manufacturing, filling and packaging, warehousing and dispatch
• dedicated building, equipment includes  HVAC systems, BP water, compressed air, cooling water, secure and required warehousing

Strong regional market growth

• SE Asia market is expected to generate $40 billion by 2020, 6% CAGR from 2015 and expected through 2030
• to meet these growing needs, governments are making long-term investments in their health infrastructures
• for those looking to build a presence in SE Asia, branded generics can serve as an ideal entry point
• Australian pharmaceutical market is expected to grow to $25.2 billion by 2020, predicted 2% CAGR

Transaction Dynamics

• 100% divestment of the business on a cash free debt free basis
• logical add-­‐on for an existing company or as a starter business for an owner manager

Process

• execution of NDA from approved parties will lead to the release of the transaction IM
• Indicative non binding offers
• due diligence
• final offer and contract negotiations